Answers are grounded in this paper and cite their sources.
all other risk groups). This identified 85 patients (10.1%) with 12.9% (95% CI 6.6-22.0) at risk of adverse outcomes and 8.2% (95% CI 3.4-16.2) at risk of PE-related deaths.Copeptin improves risk stratification of normotensive PE patients, especially when identifying patients with an increased risk of an adverse outcome.
No takes yet. Share an insight, caveat, or question.
Hellenkamp et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: